We have reported that tocilizumab in combination with anti-RCC drugs can effectively suppress tumor growth in vitro and in vivo through repressing activation of STAT3, Akt and mTOR as well as expression of HIF or SOCS3 [22, 23]. The gene discussed is SOCS3; the disease is renal cell carcinoma.